|Datasheet||Specific References||Reviews||Related Products||Protocols|
pMD18-T Simple Vector is a high-efficiency TA cloning vector constructed from pUC18, of which the initial multiple cloning sites (MCS) were destroyed. Thus the cDNA should be amplified by PCR with primers containing a restriction site for subclone. Competent cells appropriate for pUC18 are also appropriated for the Vector, e.g. JM109, DH5α, TOP10. The pMD18-T Simple Vector is 2.6kb in size. Selection of the plasmid in E. coli is conferred by the ampicillin resistance gene. The coding sequence was inserted by TA cloning at site 425.
The coding sequence can be amplified by PCR with M13-47 and RV-M primers.
|Mouse TFPI ORF mammalian expression plasmid, C-GFPSpark tag||MG50131-ACG|
|Mouse TFPI ORF mammalian expression plasmid, C-OFPSpark / RFP tag||MG50131-ACR|
|Mouse TFPI ORF mammalian expression plasmid, C-Flag tag||MG50131-CF|
|Mouse TFPI ORF mammalian expression plasmid, C-His tag||MG50131-CH|
|Mouse TFPI ORF mammalian expression plasmid, C-Myc tag||MG50131-CM|
|Mouse TFPI ORF mammalian expression plasmid, C-HA tag||MG50131-CY|
|Mouse TFPI ORF mammalian expression plasmid, N-Flag tag||MG50131-NF|
|Mouse TFPI ORF mammalian expression plasmid, N-His tag||MG50131-NH|
|Mouse TFPI ORF mammalian expression plasmid, N-Myc tag||MG50131-NM|
|Mouse TFPI ORF mammalian expression plasmid, N-HA tag||MG50131-NY|
|Mouse TFPI natural ORF mammalian expression plasmid||MG50131-UT|
|Learn more about expression Vectors|
Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of TF coagulant and signaling activities. It is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. With its Kunitz domains, TFPI exhibits significant homology with human inter-alpha-trypson inhibitor and bovin basic pancreatic trypsin inhibitor. TFPI is the natural inhibitor of TF coagulant and signaling activities. The importance of TFPI in the regulation of blood coagulation is emphasized by how its activity is modulated in human disease. In a factor (F) Xa-dependent feedback system, TFPI binds directly and inhibits the TF-FVII/FVIIa complex. Normally, TFPI exists in plasma both as a full-length molecule and as variably carboxy-terminal truncated forms. TFPI also circulates in complex with plasma lipoproteins. The levels and the dual inhibitor effect of TFPI on FXa and TF-FVII/FVIIa complex offers insight into the mechanisms of various pathological conditions triggered by TF. TFPI may play an important role in modulating TF-induced thrombogenesis and it may also provide a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In addition, Studies have shown that TFPI exhibits antiangiogenic and antimetastatic effects in vitro and in vivo. In animal models of experimental metastasis, both circulating and tumor cell-associated TFPI are shown to significantly reduce tumor cell-induced coagulation activation and lung metastasis.